- Home
- NEOV vs CYCC Comparison
NEOV vs CYCC Comparison
Compare NEOV & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- CYCC
- Stock Information
- Founded
- NEOV 2018
- CYCC 1992
- Country
- NEOV United States
- CYCC Malaysia
- Employees
- NEOV N/A
- CYCC N/A
- Industry
- NEOV Industrial Machinery/Components
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- NEOV Miscellaneous
- CYCC Health Care
- Exchange
- NEOV Nasdaq
- CYCC Nasdaq
- Market Cap
- NEOV 72.2M
- CYCC 61.2M
- IPO Year
- NEOV N/A
- CYCC N/A
- Fundamental
- Price
- NEOV $3.24
- CYCC $1.64
- Analyst Decision
- NEOV Strong Buy
- CYCC
- Analyst Count
- NEOV 1
- CYCC 0
- Target Price
- NEOV $7.50
- CYCC N/A
- AVG Volume (30 Days)
- NEOV 176.1K
- CYCC 191.0K
- Earning Date
- NEOV 05-09-2025
- CYCC 05-15-2025
- Dividend Yield
- NEOV N/A
- CYCC 150.00%
- EPS Growth
- NEOV N/A
- CYCC N/A
- EPS
- NEOV N/A
- CYCC N/A
- Revenue
- NEOV $4,255,136.00
- CYCC $14,000.00
- Revenue This Year
- NEOV $208.50
- CYCC $137.21
- Revenue Next Year
- NEOV $128.75
- CYCC N/A
- P/E Ratio
- NEOV N/A
- CYCC N/A
- Revenue Growth
- NEOV 52.64
- CYCC N/A
- 52 Week Low
- NEOV $1.80
- CYCC $1.36
- 52 Week High
- NEOV $6.11
- CYCC $49.34
- Technical
- Relative Strength Index (RSI)
- NEOV 53.45
- CYCC 33.09
- Support Level
- NEOV $2.76
- CYCC $1.36
- Resistance Level
- NEOV $3.74
- CYCC $1.82
- Average True Range (ATR)
- NEOV 0.33
- CYCC 0.36
- MACD
- NEOV -0.01
- CYCC -0.04
- Stochastic Oscillator
- NEOV 48.98
- CYCC 10.89
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.